全文获取类型
收费全文 | 8180篇 |
免费 | 717篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 145篇 |
儿科学 | 239篇 |
妇产科学 | 211篇 |
基础医学 | 1109篇 |
口腔科学 | 408篇 |
临床医学 | 646篇 |
内科学 | 1792篇 |
皮肤病学 | 145篇 |
神经病学 | 924篇 |
特种医学 | 200篇 |
外国民族医学 | 1篇 |
外科学 | 1240篇 |
综合类 | 56篇 |
预防医学 | 481篇 |
眼科学 | 164篇 |
药学 | 458篇 |
中国医学 | 13篇 |
肿瘤学 | 685篇 |
出版年
2023年 | 51篇 |
2022年 | 38篇 |
2021年 | 247篇 |
2020年 | 169篇 |
2019年 | 216篇 |
2018年 | 268篇 |
2017年 | 184篇 |
2016年 | 203篇 |
2015年 | 247篇 |
2014年 | 317篇 |
2013年 | 379篇 |
2012年 | 503篇 |
2011年 | 514篇 |
2010年 | 292篇 |
2009年 | 294篇 |
2008年 | 418篇 |
2007年 | 432篇 |
2006年 | 376篇 |
2005年 | 376篇 |
2004年 | 333篇 |
2003年 | 328篇 |
2002年 | 321篇 |
2001年 | 170篇 |
2000年 | 166篇 |
1999年 | 167篇 |
1998年 | 83篇 |
1997年 | 64篇 |
1996年 | 52篇 |
1995年 | 63篇 |
1994年 | 65篇 |
1993年 | 50篇 |
1992年 | 125篇 |
1991年 | 109篇 |
1990年 | 119篇 |
1989年 | 102篇 |
1988年 | 86篇 |
1987年 | 108篇 |
1986年 | 78篇 |
1985年 | 82篇 |
1984年 | 61篇 |
1983年 | 53篇 |
1982年 | 32篇 |
1981年 | 38篇 |
1979年 | 60篇 |
1978年 | 46篇 |
1976年 | 31篇 |
1975年 | 35篇 |
1974年 | 36篇 |
1973年 | 45篇 |
1970年 | 35篇 |
排序方式: 共有8917条查询结果,搜索用时 296 毫秒
1.
2.
3.
器官移植术是20世纪出现的针对器官功能衰竭的最有效治疗方法,每年拯救全球超过12万例患者。但供器官短缺的现状,与器官移植技术和辅助药物的发展不匹配,制约了器官移植事业的发展。我国自2015年起已成为全球器官捐献和移植大国之一,2017年公民逝世后器官捐献数量超过5 000例,占全球捐献总量的15%以上。黄洁夫教授总结的器官捐献与移植"中国模式"得到了世界卫生组织、国际移植界的高度重视和充分肯定。本文通过整理全球及各国的器官捐献与移植数据,剖析全球现状与发展趋势,进一步探索我国公民器官捐献的影响因素并提出针对性的应对策略,以期实现我国器官捐献和移植的"自给自足"。 相似文献
4.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
5.
Thaís dos Santos Fontes Pereira Carolina Cavalieri Gomes Peter A Brennan Felipe Paiva Fonseca Ricardo Santiago Gomez 《Journal of oral pathology & medicine》2019,48(1):3-9
Fibrous dysplasia is a non‐neoplastic developmental process that affects the craniofacial bones, characterized by painless enlargement as a result of bone substitution by abnormal fibrous tissue. Postzygotic somatic activating mutations in the GNAS1 gene cause fibrous dysplasia and have been extensively investigated, as well as being helpful in the differential diagnosis of the disease. Fibrous dysplasia may involve one (monostotic) or multiple bones (polyostotic), sporadically or in association with McCune‐Albright syndrome, Jeffe‐Lichenstein syndrome, or Mazabreud syndrome. This review summarizes the current knowledge on fibrous dysplasia, emphasizing the value of integrating the understanding of its molecular pathogenesis with the clinical, radiological, and histopathological features. In addition, we address important aspects related to the differential diagnosis and patient management. 相似文献
6.
A hypothesis for reactivation of pulmonary tuberculosis: How thoracic wall shape affects the epidemiology of tuberculosis 下载免费PDF全文
Aaron R. Casha Liberato Camilleri Alexander Manché Ruben Gatt Daphne Attard Wiktor Wolak Krzysztof Dudek Marilyn Gauci Christopher Giordimaina Joseph N. Grima 《Clinical anatomy (New York, N.Y.)》2015,28(5):614-620
This study was aimed at determining the cause for the high incidence of tuberculosis (TB) reactivation occurring in males with a low body mass index (BMI). Current thinking about pulmonary TB describes infection in the lung apex resulting in cavitation after reactivation. A different hypothesis is put forward for TB infection, suggesting that this occurs in subclinical apical cavities caused by increased pleural stress due to a low BMI body habitus. A finite element analysis (FEA) model of a lung was constructed including indentations for the first rib guided by paramedian sagittal CT reconstructions, and simulations were conducted with varying antero‐posterior (AP) diameters to mimic chests with a different thoracic index (ratio of AP to the transverse chest diameters). A Pubmed search was conducted about gender and thoracic index, and the effects of BMI on TB. FEA modeling revealed a tenfold increase in stress levels at the lung apex in low BMI chests, and a four‐fold increase with a low thoracic index, r2 = 0.9748 P < 0.001. Low thoracic index was related to BMI, P = 0.001. The mean thoracic index was statistically significantly lower in males, P = 0.001, and increased with age in both genders. This article is the first to suggest a possible mechanism linking pulmonary TB reactivation to low BMI due to the flattened thoracic wall shape of young male adults. The low thoracic index in young males may promote TB reactivation due to tissue destruction in the lung apex from high pleural stress levels. Clin. Anat. 28:614–620, 2015. © 2015 Wiley Periodicals, Inc. 相似文献
7.
正Proton-pump inhibitors (PPIs) are first line therapy for most gastroesophageal acid-related disorders. They include reflux disorders, Helicobacter pylori infections, Zollinger-Ellison syndrome, and gastroesophageal malignancies. In clinical 相似文献
8.
Rajnish Mago MD John-Paul Gomez MD Namita Gupta MBBS Elisabeth J. S. Kunkel MD 《Current psychiatry reports》2006,8(3):228-233
Anxiety disorders and anxiety symptoms are highly prevalent in the general population and more so in the medically ill. They
have a number of negative consequences for these patients and may worsen the outcome of the medical illness and increase health
care utilization. In the evaluation of these patients, it is of paramount importance to identify the etiology of the anxiety
and, in particular, to differentiate primary from secondary anxiety. Management includes medications (especially benzodiazepines
and selective serotonin reuptake inhibitors) and psychotherapy (particularly cognitive-behavioral therapy). 相似文献
9.
10.
Ruben A. Mesa MD Alfonso Quintás-Cardama MD Srdan Verstovsek MD PhD 《Current hematologic malignancy reports》2007,2(1):25-33
Myelofibrosis with myeloid metaplasia (MMM) is currently classified as a classic (ie, BCR-ABL-negative) myeloproliferative
disorder characterized by anemia, multiorgan extramedullary hematopoiesis, constitutional symptoms, and premature death from
either leukemic transformation or other disease complications. Stem cell transplantation can be curative, but many patients
either are not appropriate candidates or do not choose to accept the significant risks associated with transplantation. Current
pharmacologic therapy has been beneficial mainly in terms of palliating disease-associated cytopenias, constitutional symptoms,
splenomegaly, and other organ damage from excess myeloproliferation. Novel treatment strategies are under investigation, including
targeted inhibition of JAK2V617F, the activating tyrosine kinase point mutation present in about half of patients with MMM. In this article, we review both
the old and new pharmacologic options for MMM. 相似文献